Nu-Med Plus, Inc. (NUMD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US67021R1041
Nu-Med Plus, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -48,955.00 USD |
| EBIT | -48,955.00 USD |
| Net income | -56,182.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Nu-Med Plus, Inc.
Nu-Med Plus, Inc., a medical device company, engages in the design, innovation, development, enhancement, and commercialization of medical devices worldwide. The company develops a nitric oxide generating formulation; a hospital bedside nitric oxide delivery system; a clinical unit for use in medical clinics and rehabilitation centers. It is also involved in the development of a mobile rechargeable device to deliver nitric oxide gas; and a nitric oxide system that can be used for research applications, as well as a mobile/portable rechargeable device to deliver inhaled nitric oxide gas. Nu-Med Plus, Inc. was incorporated in 2011 and is based in Port Jefferson, New York.
More stocks
- Protagenic Therapeutics, Inc.\new (PTIX)
- CEMTREX INC (CETX)
- Mentor Capital, Inc. (MNTR)
- Karyopharm Therapeutics Inc. (KPTI)
- Catheter Precision, Inc. (VTAK)
- My Size, Inc. (MYSZ)
- Presidio Property Trust, Inc. (SQFT)
- Sky Century Investment, Inc. (SKYI)
- Dream Homes & Development Corp. (DREM)
- Yubo International Biotech Ltd (YBGJ)
- Naploy Corp. (NPLY)
- iPower Inc. (IPW)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.